# Turn Therapeutics Inc. (TTRX) fundamentals

Data as of 2026-09-09. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $12.66, market value $384 million.

## Valuation
- **P/E (trailing): n/a** (negative earnings). Turn Therapeutics Inc. reported negative earnings over the last twelve months, so the P/E is not meaningful; use price-to-sales, EV/EBITDA and free-cash-flow yield instead.
- **Price / book: 550.4×**. The shares trade at 550.4× book value; most of the value is in earnings power and intangibles rather than the balance sheet.

## Profitability
- **Return on equity: -68.2%**. Return on equity is negative because earnings are negative.

## Growth
- **EPS growth (1 yr): -71.4%**. Earnings per share fell 71.4%.

## Financial health
- **Current ratio: 0.87** (quick 0.87). Current liabilities exceed current assets, so the company depends on ongoing cash generation or refinancing to pay the next year's bills.
- **Piotroski F-score: 2/9**. 2 of 9 checks pass: weak or deteriorating financials.

## Dividends
- **Dividend: none**. Turn Therapeutics Inc. does not currently pay a dividend.

## Analyst view
- **Analyst consensus: strong_buy** (1 analyst). 1 analysts cover Turn Therapeutics Inc.; the consensus is strong_buy, with an average price target of $26.00 (+105% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **From 52-week high: -52.2%** (392.6% above the low). Trading 52% below its 52-week high, deep in a drawdown.
- **200-day average: above**. The price sits above its 200-day moving average, the usual definition of an uptrend.
- **RSI (14-day): 53**. An RSI of 53 is neutral.
- **Beta (1 yr): 1.56** (volatility 109%). Beta of 1.56 against the S&P 500: the shares move much more than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=TTRX · Page: https://foliofundamentals.com/stocks/ttrx

Not investment advice.